Targeting the CaN/FoxO1/FABP4 Axis: Mechanistic Insights into Atherosclerosis Prevention

Study Background and Research Question

Atherosclerosis is characterized by chronic inflammation and progressive lipid accumulation within the arterial wall, ultimately leading to major cardiovascular events. Central to atherogenesis is the transformation of macrophages into lipid-laden foam cells. While the role of lipid metabolism and inflammation is well established, the precise molecular triggers linking endoplasmic reticulum (ER) stress, calcium signaling, and foam cell formation remain incompletely understood. The reference study (Tong et al., 2025) investigates whether dysfunction of the sarcoplasmic/endoplasmic reticulum Ca²⁺ ATPase 2 (SERCA2) enzyme exacerbates atherosclerosis by activating the calcineurin (CaN)/forkhead box O1 (FoxO1)/fatty acid binding protein 4 (FABP4) pathway, thereby promoting foam cell formation and disease progression.

Key Innovation from the Reference Study

The central innovation of this research is the identification of a mechanistic link between SERCA2 dysfunction and the activation of the CaN/FoxO1/FABP4 signaling cascade in bone marrow-derived macrophages (BMDMs). The study demonstrates that a pathogenic mutation (C674S) in SERCA2 triggers nuclear translocation of FoxO1 and upregulation of its downstream target FABP4, which in turn drives aberrant lipid metabolism and foam cell formation. Importantly, pharmacological inhibition of FABP4 — a lipid chaperone implicated in insulin resistance and inflammation — was shown to reverse these detrimental effects, reducing foam cell formation and atherogenesis in vivo. This work positions the CaN/FoxO1/FABP4 pathway as a critical mediator of atherosclerotic progression and a promising therapeutic target.

Methods and Experimental Design Insights

The study utilized heterozygous SERCA2 C674S knock-in (SKI) mice to model SERCA2 dysfunction under pathological conditions. Metabolomic profiling of serum from both SKI and wild-type mice enabled a detailed analysis of systemic lipid metabolism. Histological examination of the aorta and aortic root quantified atherosclerotic plaque burden. In vitro, BMDMs were isolated to assess protein expression, lipid uptake, and foam cell formation via immunoblotting, immunofluorescence, and lipid staining. The expression of key pathway components (CaN, FoxO1, FABP4) was interrogated using both genetic and pharmacological tools. Notably, the selective FABP4 inhibitor BMS 309403 was used to dissect the contribution of FABP4 to these processes. The study also employed partial genetic deficiency of FABP4 to corroborate pharmacological findings, providing mechanistic clarity and translational relevance.

Protocol Parameters

• Mouse model: Heterozygous SERCA2 C674S knock-in (SKI) mice to evaluate the effect of SERCA2 dysfunction on atherogenesis.
• Pharmacological intervention: Administration of selective FABP4 inhibitor BMS 309403 to assess impact on lipid accumulation and foam cell formation.
• In vitro BMDM workflow: Isolate bone marrow-derived macrophages, treat with BMS 309403 (suggested working concentrations: 1–25 μM), and evaluate lipid uptake and foam cell formation after 24–72 hours.
• Histology: Oil Red O and immunofluorescence staining of aortic tissue to quantify plaque area and lipid content.
• Biochemical endpoints: Assess expression of CaN, FoxO1, FABP4, and cholesterol efflux transporters (ABCA1, ABCG1) via immunoblotting and qPCR.

Core Findings and Why They Matter

The study found that SERCA2 dysfunction in SKI mice led to increased atherosclerotic plaque formation, accompanied by elevated expression of CaN, nuclear FoxO1, and FABP4 in BMDMs. These changes correlated with excessive lipid uptake, reduced cholesterol efflux, and pronounced foam cell formation. Critically, pharmacological inhibition of FABP4 — either through BMS 309403 or genetic knockdown — normalized lipid handling, decreased foam cell abundance, and significantly reduced atherosclerotic lesion size (Tong et al., 2025). This work directly implicates the CaN/FoxO1/FABP4 axis as a pathogenic driver in atherosclerosis and provides experimental proof-of-concept for targeting FABP4 in preclinical models. These findings align with the broader understanding of FABP4’s role in inflammation and lipid metabolism, and extend its significance to disease contexts driven by ER stress and calcium signaling.

Comparison with Existing Internal Articles

Several internal resources further contextualize the translational impact of these findings. "BMS 309403: FABP4 Inhibitor Workflows for Atherosclerosis Research" provides detailed experimental protocols for deploying BMS 309403 in lipid metabolism and inflammation models, supporting the workflow strategies validated in the reference study. Similarly, "BMS 309403 and FABP4: Translational Strategies in Atherosclerosis" discusses the mechanistic rationale and protocol optimization for targeting FABP4 in cardiovascular models, reinforcing the importance of the CaN/FoxO1/FABP4 axis. These articles elaborate on troubleshooting, dose selection, and the translational gap between preclinical and clinical research, providing practical resources for researchers building on the present findings. Collectively, these resources highlight the specificity and potency of BMS 309403 as a tool to interrogate FABP4’s role in atherosclerosis and related metabolic diseases.

Limitations and Transferability

While the study robustly links SERCA2 dysfunction to atherosclerosis via the CaN/FoxO1/FABP4 pathway, several limitations temper the immediate transferability of these results. The primary reliance on a murine SKI model, while pathophysiologically relevant, does not fully recapitulate human cardiovascular disease complexity. Additionally, long-term safety and efficacy data for pharmacological FABP4 inhibition remain limited, especially in the context of chronic metabolic disease. The study does, however, offer a strong mechanistic rationale for further clinical exploration, and the use of both genetic and pharmacological approaches strengthens the causal inference. Researchers should consider the differences in FABP4 function and regulation across species, as well as potential off-target effects of small molecule inhibitors, when designing translational studies.

Research Support Resources

To facilitate similar experimental workflows, researchers can utilize BMS 309403 (SKU B7794), a potent and selective FABP4 inhibitor with validated utility in both in vitro and in vivo models of atherosclerosis and type 2 diabetes, as described in the reference study and related internal protocols. BMS 309403 is DMSO- and ethanol-soluble, with recommended working concentrations of 1–25 μM for cell-based assays and robust performance in metabolic disease models. For detailed protocols and troubleshooting advice, the above internal articles and APExBIO’s product documentation provide additional technical guidance for researchers seeking to dissect FABP4’s role in lipid metabolism, inflammation, and cardiovascular pathology.